Philpott and Girardin [53] reported that IBD patients carrying NOD2 mutations exhibited decreased transcription of IL-10; thus, it is suspected that patients in Cluster 3 are more likely to carry NOD2 mutations. This evidence concerns the gene IL10 and inflammatory bowel disease.